NCT03099356RecruitingPhase 2
An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
University of Michigan Rogel Cancer Center2 sites in 1 country22 target enrollmentStarted: April 27, 2017Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 22
- Locations
- 2
- Primary Endpoint
- Percentage of patients that respond to treatment
Study Overview
Brief Summary
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically documented differentiated thyroid cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatment
- •Measurable disease (>10 mm) and have progression of disease based on RECIST criteria. Previously irradiated tumor lesions are not considered measurable unless they have progressed since radiation.
- •Previous failure of Iodine-131 (131I) therapy or not candidates to receive 131I as assessed by treating physician.
- •Age ≥ 18 years
- •ECOG (Eastern Cooperative Oncology Group) performance status 0-2
- •Life expectance of ≥ 12 weeks
- •131I therapy not allowed within 24 weeks before entry (4 weeks if negative post-treatment scan)
- •Adequate organ and marrow function
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment
- •Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
- •Willingness and ability to comply with scheduled visits, treatment plans, including willingness to take study medication, laboratory tests, and other study procedures
Exclusion Criteria
- •Inability to obtain Foundation One testing on archival tissue, or, lack of previous Next Generation Sequencing
- •Chemotherapy, tyrosine kinase inhibitor, or radiation therapy within 4 weeks
- •Prior experimental therapy within 4 weeks of planned start of this trial
- •131I therapy within 24 weeks before entry (4 weeks if negative post-treatment scan)
- •Previous treatment with an mTOR inhibitor
- •Patients who are currently receiving treatment with strong inhibitors or inducers of CYP3A4 or P-glycoprotein that cannot be discontinued at least one week prior to the start of treatment with Cyclophosphamide and Sirolimus
- •Impairment of GI (gastrointestinal) function or GI disease that may significantly alter the absorption of study medications (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection) including dependence on a G-Tube for administration of medications.
- •A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment
- •Patients with known sensitivities to either cyclophosphamide and/or sirolimus
- •Patients with known urinary outflow obstruction
- •Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
- •Patients (male and female) having procreative potential who are not willing or not able to use adequate contraception or practicing abstinence
- •Women who are pregnant or breast-feeding
- •Patients residing in prison
Arms & Interventions
Cyclophosphamide and Sirolimus
Experimental
Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
Intervention: Cyclophosphamide (Drug)
Cyclophosphamide and Sirolimus
Experimental
Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
Intervention: Sirolimus (Drug)
Outcomes
Primary Outcomes
Percentage of patients that respond to treatment
Time Frame: Patients will be followed for response until progression or up to 2 Years
The primary measure of efficacy will be the overall response rate (ORR) which is defined as those achieving either complete response (CR) or partial response (PR). Partial response is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Complete response is defined as Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart (there can be no appearance of new lesions) and the disappearance of all non-target lesions and normalization of tumor marker level.
Secondary Outcomes
- The number of patients that experience toxicity(Patients are followed for toxicity up to 30 days after the last dose of study drug)
- Median overall survival time(Patients will be followed until death or up to 2 years)
- Median progression free survival time(Patients will be followed for response until progression or up to 2 Years)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Terminated
Phase 1
Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorMultiple Sclerosis (MS) - Relapsing-remittingNCT00095329National Institute of Allergy and Infectious Diseases (NIAID)14
Active, not recruiting
Not Applicable
TMC114-TiDP29-C228 – A safety study to evaluate the antiviral activity of darunavir (DRV) in combination with ritonavir (rtv) in HIV 1 infected children from 3 years to below 6 years of ageThe purpose of this Phase II trial is to evaluate the pharmacokinetics (blood levels), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in combination with other antiretroviral drugs (ARVs), in treatment-experienced HIV 1 infected children aged from 3 years to < 6 years and weighing between 10 kg and < 20 kg .MedDRA version: 16.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2008-004630-25-Outside-EU/EEATibotec Pharmaceuticals24
Terminated
Phase 2
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)Hepatitis CNCT02956629Merck Sharp & Dohme LLC282
Active, not recruiting
Not Applicable
A safety study to evaluate the antiviral activity of darunavir in combination with ritonavir in HIV 1 infected adolescents between 12 and 18 years of age who have not received previous treatment with antiretroviral drugsHIV-1MedDRA version: 14.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-004631-37-Outside-EU/EEATibotec Pharmaceuticals12
Active, not recruiting
Phase 1
A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 years.This trial will be referred to as DIONE.Estudio en Fase II, abierto, para evaluar la farmacocinética, seguridad, tolerabilidad y actividad antiviral de DRV/rtv una vez al día en adolescentes infectados por VIH-1 de entre 12 y < 18 años de edad no tratados. Nos referiremos a este estudio como DIONE. - DIONEHIV-1VIH-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2008-004631-37-ESTibotec Pharmaceuticals12